Risks Emerge for New Class of Diabetes Drugs

Risks Emerge for New Class of Diabetes Drugs
Risks Emerge for New Class of Diabetes Drugs
Last updated:

A New Class of Diabetes Drugs: Adverse Events and Risks

A new class of diabetes drugs that has been available for a little over three years have become immensely popular with doctors and patients, even though the pills have a host of adverse events and risks.

The first SGLT2 (first sodium-glucose cotransporter-2) inhibitor to hit the market, back in 2013, was Invokana (canagliflozin). Since then, the FDA has granted approval to 2 other oral medications in this class, Farxiga (dapagliflozin) and Jardiance (empagliflozin). By the fourth quarter of 2015, the trio accounted for 2 million prescriptions, an amazing six-fold increase since the first quarter of 2014, according to IMS Health.

Despite their growing popularity, SGLT2s have been associated with many adverse event reports and other troubling side effects based on clinical trials, according to a new report from the Institute for Safe Medication Practices (ISMP). These include: life-threatening ketoacidosis; electrolyte imbalances leading to severe dehydration and other problems; acute kidney injury; frequent genital infections, primarily fungal; and increased risk of bone fracture.

For example, interim data from a cardiovascular outcomes trial for Inovkana released in January found that the drug caused a statistically significant increased risk of bone fracture (4.0% v. 2.6%) compared to a placebo group treated with other medications. There was also an increased risk of foot and toe amputation from the same trial.

ISMP also found emerging signals of three other adverse effects: possible increased risk of limb amputation; pancreatitis; and hypersensitivity. They added that the number of cases increased for other reported adverse effects, especially sepsis and urosepsis, kidney stones. and abnormal weight loss.

Last month, the FDA strengthened the warnings on SGLT2 drugs regarding acute kidney injury “based on recent reports.”

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Recommend More Articles Like This?

Show Comments (0)
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x